Table 2 Treatment follow-up results and outcomes
Treatment follow-up results and outcomes | n (%) |
|---|---|
AST elevation | |
Normal and < 3 times | 441 (90.18) |
≥ 3 times | 48 (9.82) |
ALT elevation | |
Normal and < 3 times | 462 (94.48) |
≥ 3 times | 27 (5.52) |
Total bilirubin elevation | |
< 3 mg/dL | 463 (95.07) |
≥ 3 mg/dL | 24 (4.93) |
Hepatotoxicity side effect during treatment | |
Yes | 53 (10.84) |
No | 436 (89.16) |
Sputum AFB follow up at the end of intensive phase | |
Positive | 31 (6.34) |
Negative | 420 (85.89) |
Not performed | 38 (7.77) |
Transferred out to other treatment units | 2 (0.41) |
Outcome (n = 487)a | |
Cure | 268 (55.03) |
Complete | 161 (33.06) |
Die | 40 (8.21) |
Loss to follow-up | 16 (3.29) |
Fail | 2 (0.41) |